[Administrative policy concerning the issue of hepatitis virus infection by blood products].
Kanai
Masatoshi
M
Blood and Blood Products Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare.
D001688:Biological Products / Q000009:adverse effects; D001779:Blood Coagulation Factors; D004340:Drug Contamination / Q000517:prevention & control; D004335:Drug and Narcotic Control / Q000331:legislation & jurisprudence; D005340:Fibrinogen; D006077:Government Agencies; D006509:Hepatitis B / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D006526:Hepatitis C / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007564:Japan / Q000453:epidemiology; D012449:Safety; D013997:Time Factors; D065227:Transfusion Reaction
D001688:Biological Products; D001779:Blood Coagulation Factors; D005340:Fibrinogen